不对称二甲基精氨酸：儿科医学中的临床应用。

Asymmetric dimethylarginine: clinical applications in pediatric medicine.

机构信息

Department of Pediatrics, Chang Gung Memorial Hospital-Kaohsiung Medical Center, College of Medicine, Chang Gung University, 123 Dabi Road, Kaohsiung, Taiwan.

出版信息

J Formos Med Assoc. 2011 Feb;110(2):70-7. doi: 10.1016/S0929-6646(11)60012-0.

DOI:10.1016/S0929-6646(11)60012-0

PMID:21377060

Abstract

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS). Growing evidence indicates that ADMA plays an important role in the initiation and progression of a variety of adulthood diseases, especially in the cardiovascular and renal systems. However, the study of ADMA in pediatric diseases has just begun. This review provides an overview of potential clinical applications of ADMA in pediatric practice, with an emphasis on the following areas: the biochemistry and pathophysiology of ADMA; clinical ramifications of elevated ADMA levels in pediatric population; age-related normal reference ranges of ADMA; methodology for measuring ADMA; current and potential agents to reduce ADMA; and the problems that must be addressed before use of ADMA in pediatric medicine. ADMA will soon be available for use as a biomarker and therapeutic target in the pediatric population.

摘要

不对称二甲基精氨酸（ADMA）是一氧化氮合酶（NOS）的内源性抑制剂。越来越多的证据表明，ADMA 在多种成人疾病的发生和发展中起着重要作用，尤其是在心血管和肾脏系统。然而，ADMA 在儿科疾病中的研究才刚刚开始。本文综述了 ADMA 在儿科临床实践中的潜在应用，重点介绍以下几个方面：ADMA 的生物化学和病理生理学；儿科人群中 ADMA 水平升高的临床意义；ADMA 的年龄相关正常参考范围；ADMA 的测量方法；目前和潜在的降低 ADMA 的药物；以及在儿科医学中使用 ADMA 之前必须解决的问题。ADMA 很快将可作为儿科人群的生物标志物和治疗靶点。